Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00232102 · ClinicalTrials.gov registry record · Phase 3
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 423
- Enrollment target
NCT00232102: Completed Phase 3 study, sponsored by Novartis.
NCT00232102 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 423 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00232102, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 423 participants
- Enrollment target
Study Summary
This study is being done to evaluate the long-term safety of tegaserod in women with symptoms of dyspepsia who have completed the core study. Tegaserod will be evaluated at 6 mg twice daily.
Interventions
- DRUG Tegaserod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 423 participants |
| Start Date | 2004-09 |
| Est. Completion | 2006-08 |
| Phase | Phase 3 |
What the finished NCT00232102 record still lists
NCT00232102 is an interventional study that assigns participants to a tested intervention. The registered 423 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower).
The record links to 0 conditions, and to 1 intervention - of which Tegaserod is the first listed.
NCT00232102 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00232102 about?
NCT00232102 is a clinical study titled "Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia". This study is being done to evaluate the long-term safety of tegaserod in women with symptoms of dyspepsia who have completed the core study. Tegaserod will be evaluated at 6 mg twice daily.
What is the current status of trial NCT00232102?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 423 participants. The study started on 2004-09. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00232102?
The interventions under investigation include: Tegaserod (DRUG).
Who is sponsoring clinical trial NCT00232102?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00232102's enrollment target sits among peer trials
423 885th of 2000 higher than 1,115 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06935591 · 423 participants · NA
Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study
- NCT07128628 · 423 participants · Phase 2
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
- NCT05632770 · 424 participants · NA
A Deployment Focused Pragmatic Trial of Optimal Stepped Care Intervention Targeting PTSD and Comorbidity for Acutely Hospitalized Injury Survivors Treated in US Trauma Care Systems
- NCT05733767 · 424 participants · Phase 2
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia